These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

356 related items for PubMed ID: 23658373

  • 1. Incidence and risk of treatment-related mortality in cancer patients treated with the mammalian target of rapamycin inhibitors.
    Choueiri TK, Je Y, Sonpavde G, Richards CJ, Galsky MD, Nguyen PL, Schutz F, Heng DY, Kaymakcalan MD.
    Ann Oncol; 2013 Aug; 24(8):2092-7. PubMed ID: 23658373
    [Abstract] [Full Text] [Related]

  • 2. Incidence and risk of treatment-related mortality with mTOR inhibitors everolimus and temsirolimus in cancer patients: a meta-analysis.
    Qi WX, Huang YJ, Yao Y, Shen Z, Min DL.
    PLoS One; 2013 Aug; 8(6):e65166. PubMed ID: 23785409
    [Abstract] [Full Text] [Related]

  • 3. Hematologic toxicities associated with mTOR inhibitors temsirolimus and everolimus in cancer patients: a systematic review and meta-analysis.
    Xu J, Tian D.
    Curr Med Res Opin; 2014 Jan; 30(1):67-74. PubMed ID: 24028709
    [Abstract] [Full Text] [Related]

  • 4. Risk of infections in renal cell carcinoma (RCC) and non-RCC patients treated with mammalian target of rapamycin inhibitors.
    Kaymakcalan MD, Je Y, Sonpavde G, Galsky M, Nguyen PL, Heng DY, Richards CJ, Choueiri TK.
    Br J Cancer; 2013 Jun 25; 108(12):2478-84. PubMed ID: 23736025
    [Abstract] [Full Text] [Related]

  • 5. First-line Mammalian target of rapamycin inhibition in metastatic renal cell carcinoma: an analysis of practice patterns from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Harshman LC, Kroeger N, Rha SY, Donskov F, Wood L, Tantravahi SK, Vaishampayan U, Rini BI, Knox J, North S, Ernst S, Yuasa T, Srinivas S, Pal S, Heng DY, Choueiri TK.
    Clin Genitourin Cancer; 2014 Oct 25; 12(5):335-40. PubMed ID: 24787966
    [Abstract] [Full Text] [Related]

  • 6. Treatment outcome with mTOR inhibitors for metastatic renal cell carcinoma with nonclear and sarcomatoid histologies.
    Voss MH, Bastos DA, Karlo CA, Ajeti A, Hakimi AA, Feldman DR, Hsieh JJ, Molina AM, Patil S, Motzer RJ.
    Ann Oncol; 2014 Mar 25; 25(3):663-668. PubMed ID: 24458473
    [Abstract] [Full Text] [Related]

  • 7. mTOR inhibitors in advanced renal cell carcinoma.
    Voss MH, Molina AM, Motzer RJ.
    Hematol Oncol Clin North Am; 2011 Aug 25; 25(4):835-52. PubMed ID: 21763970
    [Abstract] [Full Text] [Related]

  • 8. Incidence and risk of rash to mTOR inhibitors in cancer patients--a meta-analysis of randomized controlled trials.
    Shameem R, Lacouture M, Wu S.
    Acta Oncol; 2015 Jan 25; 54(1):124-32. PubMed ID: 24914484
    [Abstract] [Full Text] [Related]

  • 9. Differences in adverse event profiles between everolimus and temsirolimus and the risk factors for non-infectious pneumonitis in advanced renal cell carcinoma.
    Nozawa M, Ohzeki T, Tamada S, Hongo F, Anai S, Fujimoto K, Miki T, Nakatani T, Fukasawa S, Uemura H.
    Int J Clin Oncol; 2015 Aug 25; 20(4):790-5. PubMed ID: 25342378
    [Abstract] [Full Text] [Related]

  • 10. Treatment-related fatigue with everolimus and temsirolimus in patients with cancer-a meta-analysis of clinical trials.
    Peng L, Zhou Y, Ye X, Zhao Q.
    Tumour Biol; 2015 Feb 25; 36(2):643-54. PubMed ID: 25281033
    [Abstract] [Full Text] [Related]

  • 11. Attributable Risk of Infection to mTOR Inhibitors Everolimus and Temsirolimus in the Treatment of Cancer.
    Garcia CA, Wu S.
    Cancer Invest; 2016 Nov 25; 34(10):521-530. PubMed ID: 27791402
    [Abstract] [Full Text] [Related]

  • 12. Everolimus in renal cell carcinoma.
    Wang Y.
    Drugs Today (Barc); 2010 Aug 25; 46(8):557-66. PubMed ID: 20830316
    [Abstract] [Full Text] [Related]

  • 13. Incidence and risk of high-grade stomatitis with mTOR inhibitors in cancer patients.
    Shameem R, Lacouture M, Wu S.
    Cancer Invest; 2015 Mar 25; 33(3):70-7. PubMed ID: 25635371
    [Abstract] [Full Text] [Related]

  • 14. Everolimus vs. temsirolimus for advanced renal cell carcinoma: use and use of resources in the US Oncology Network.
    Vogelzang NJ, Bhor M, Liu Z, Dhanda R, Hutson TE.
    Clin Genitourin Cancer; 2013 Jun 25; 11(2):115-20. PubMed ID: 23063578
    [Abstract] [Full Text] [Related]

  • 15. A Randomised Phase 2 Study of AZD2014 Versus Everolimus in Patients with VEGF-Refractory Metastatic Clear Cell Renal Cancer.
    Powles T, Wheater M, Din O, Geldart T, Boleti E, Stockdale A, Sundar S, Robinson A, Ahmed I, Wimalasingham A, Burke W, Sarker SJ, Hussain S, Ralph C.
    Eur Urol; 2016 Mar 25; 69(3):450-6. PubMed ID: 26364551
    [Abstract] [Full Text] [Related]

  • 16. First-Line and Sequential Use of Pazopanib Followed by Mammalian Target of Rapamycin Inhibitor Therapy Among Patients With Advanced Renal Cell Carcinoma in a US Community Oncology Setting.
    Vogelzang NJ, Hackshaw MD, Hutson TE, Bhowmik D, Yap M, Rembert D, Jonasch E.
    Clin Genitourin Cancer; 2015 Jun 25; 13(3):210-7. PubMed ID: 25498215
    [Abstract] [Full Text] [Related]

  • 17. Everolimus for the treatment of advanced renal cell carcinoma.
    Amato R.
    Expert Opin Pharmacother; 2011 May 25; 12(7):1143-55. PubMed ID: 21470068
    [Abstract] [Full Text] [Related]

  • 18. Rechallenge with mTOR inhibitors in metastatic renal cell carcinoma patients who progressed on previous mTOR inhibitor therapy.
    Maj-Hes A, Medioni J, Scotte F, Schmidinger M, Kramer G, Combe P, Gornadha Y, Elaidi R, Oudard S.
    Oncology; 2013 May 25; 85(1):8-13. PubMed ID: 23797151
    [Abstract] [Full Text] [Related]

  • 19. Everolimus and temsirolimus are not the same second-line in metastatic renal cell carcinoma. A systematic review and meta-analysis of literature data.
    Iacovelli R, Santoni M, Verzoni E, Grassi P, Testa I, de Braud F, Cascinu S, Procopio G.
    Clin Genitourin Cancer; 2015 Apr 25; 13(2):137-41. PubMed ID: 25160521
    [Abstract] [Full Text] [Related]

  • 20. Biological toxicities as surrogate markers of efficacy in patients treated with mTOR inhibitors for metastatic renal cell carcinoma.
    Jebali M, Elaidi R, Brizard M, Fouque J, Takouchop C, Sabatier B, Oudard S, Medioni J.
    BMC Cancer; 2017 Jan 06; 17(1):27. PubMed ID: 28061764
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.